Patents by Inventor Bethany Lyn Kormos

Bethany Lyn Kormos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors
    Publication number: 20150366874
    Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: August 31, 2015
    Publication date: December 24, 2015
    Applicant: PFIZER INC.
    Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Antonia Friederike Stepan, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest
  • Triazine Derivatives
    Publication number: 20150353579
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Application
    Filed: August 19, 2015
    Publication date: December 10, 2015
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors
    Patent number: 9156845
    Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 13, 2015
    Assignee: Pfizer Inc.
    Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Antonia Friederike Stepan, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest
  • Triazine derivatives
    Patent number: 9145427
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: September 29, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Byrce Tuttle, Patrick Robert Verhoest
  • Triazine Derivatives
    Publication number: 20150080401
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Triazine derivatives
    Patent number: 8933224
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: January 13, 2015
    Assignee: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Triazine Derivatives
    Publication number: 20140329820
    Abstract: The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.
    Type: Application
    Filed: April 30, 2014
    Publication date: November 6, 2014
    Applicant: Pfizer Inc.
    Inventors: Thomas Allen Chappie, Christopher John Helal, Bethany Lyn Kormos, Jamison Bryce Tuttle, Patrick Robert Verhoest
  • Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors
    Publication number: 20140005183
    Abstract: The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 2, 2014
    Inventors: Paul Galatsis, Matthew Merrill Hayward, Bethany Lyn Kormos, Travis T. Wager, Lei Zhang, Antonia Friederike Stepan, Jaclyn Louise Henderson, Ravi G. Kurumbail, Patrick Robert Verhoest